Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 6/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.33 |
| ▸ | AR | P10275 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30613096 | 0.84 | CYP19A1 (0.57) | CYP19A1RECQL | |
| SCHEMBL13251206 | 0.78 | ATM (0.38) | CYP19A1STAT3RECQLESR2AR | |
| SCHEMBL19222394 | 0.72 | ICAM1 (0.38) | CYP19A1STAT3RECQLAR | |
| Santamarin SCHEMBL2551388 | 0.71 | PKM (0.48) | CYP19A1 | |
| Douglanin SCHEMBL30379418 | 0.71 | PKM (0.48) | CYP19A1 | |
| Santamarin SCHEMBL22305508 | 0.71 | PKM (0.48) | CYP19A1 | |
| SCHEMBL21214112 | 0.69 | ESR2 (0.34) | CYP19A1ESR1ESR2AR | |
| SCHEMBL17086994 | 0.67 | TAS2R46 (0.39) | STAT3 | |
| SCHEMBL7741874 | 0.63 | ALDH1A1 (0.56) | — | |
| SCHEMBL13251201 | 0.63 | ALDH1A1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470875-B2 | Use of parthenolide derivatives as antileukemic and cytotoxic agents | UNIVERSITY OF KENTUCKY (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100184745-A1 | USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS | UNIVERSITY OF KENTUCKY (US) | 2010-07-22 | — | — | US | disclosed |
| US-7678904-B2 | or to treat autoimmune and inflammatory disorders; improved water solubility characteristics | UNIVERSITY OF KENTUCKY (US) | 2010-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184745-A1 | USE OF PARTHENOLIDE DERIVATIVES AS ANTILEUKEMIC AND CYTOTOXIC AGENTS | NR1H2, NR1H3, NCOR2 | CYP19A1 664/4885STAT3 237/4885RECQL 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.